ClinicalTrials.gg

Scleroderma, Systemic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 613 studies for Scleroderma, Systemic across more than 10 countries. 221 are recruiting or about to start. 364 of them are mainly about Scleroderma, Systemic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Scleroderma, Diffuse too: 772 studies, 257 open.

ClinicalTrials.gov finds 823 studies for Scleroderma, Systemic. How that becomes 607 here

This page counts the studies the registry files under Scleroderma, Systemic, and those it files under no condition that list Scleroderma, Systemicthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 823Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −159Filed under a narrower condition, counted on its own pageScleroderma, Diffuse 159
  3. −11List Scleroderma, Systemic as a condition, but the registry did not file them under itMost often written as “SSc-Systemic Sclerosis” (4), “Lung Disease With Systemic Sclerosis” (2), and “Systemic Sclerosis Patients With Digital Ulcers” (1). The registry filed them under other conditions only, most often Lupus Erythematosus, Systemic (5) and Lung Diseases, Interstitial (3).
  4. −46Match it another way13 name it in the title, 3 in a keyword, and 30 by a synonym or other text the search reads.
  5. 607The count on this page12 of them list Scleroderma, Systemic in their own words; the registry filed them under no condition.

Status

Completed
251
Recruiting
145
Not yet recruiting
66
Status unknown
58
Terminated
39
Active, not recruiting
24

Phase

Phase 2
168
Phase 1
107
Phase 3
53
Early Phase 1
28
Phase 4
18

Where

United States
165
France
132
China
82
United Kingdom
56
Germany
52
Italy
48

Who develops what

Add Scleroderma, Systemic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 44 programs from 36 companies, 19 with this as their studies’ main aim; 6 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Bristol-Myers Squibb, AbbVie and AstraZeneca here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07335562 · Bristol-Myers Squibb · Phase 3 · live · background · “Fludarabine” · registered Jan 2026
  • NCT06733935 · Nkarta, Inc. · Phase 2 · live · background · “Fludarabine” · registered Dec 2024
Beijing Biotech18% of its industry studies22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07335562 · Bristol-Myers Squibb · Phase 3 · live · background · “Cyclophosphamide” · registered Jan 2026
  • NCT06733935 · Nkarta, Inc. · Phase 2 · live · background · “Cyclophosphamide” · registered Dec 2024
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
anifrolumabApproved: US 2021 · EU 2022☆ Track2 live phase-3 studies: NCT05925803, NCT07691970AstraZeneca
zolacabtagene autoleucel☆ Track1 live phase-3 study: NCT07335562Bristol-Myers Squibb
tocilizumabApproved: US 2010 · EU 2009☆ Track1 live phase-3 study: NCT07335562Bristol-Myers Squibb
nerandomilastApproved: US 2025 · EU 2026☆ Track1 live phase-3 study: NCT07497087Boehringer Ingelheim
ABBV-722☆ Track1 live phase-3 study: NCT07933211AbbVie

The 5 in phase 3 with the nearest primary completion, of 44 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.PRO-203 · Prolium Bioscience, Inc · Phase 2 main aimNCT07641634 A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. — primary endpoint: Incidence of Adverse Events and Laboratory Abnormalities [Safety and Tolerability] · 44 enrolled
  • 6 Jan 2027 est.anifrolumab · AstraZeneca · Phase 3 main aimNCT05925803 Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) — primary endpoint: Number of participants responding to treatment based on the Revised Composite Response Index in Systemic Sclerosis (CRISS-25) · 314 enrolled
  • Feb 2027 est.treprostinil · Liquidia Technologies, Inc. · Phase 2 main aimNCT07748000 A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks — primary endpoint: Participant incidence of tolerated dose(s) of LIQ861 defined as a dose level or dose regimen at which ≥80% of participants complete the Treatment Period with ≥80% compliance without permanent discontinuation of LIQ861 due to a TEAE · 75 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Scleroderma, Systemic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 4 open · Alkylating agents 4 open · Antimetabolites 2 open · JAK inhibitors 2 open · Endothelin receptor antagonists 15

Coming up

60studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger. 19 (13%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 16 (11%) take healthy volunteers.

Recruiting studies that take each age, of 145
AgeWomenMen
1017 (12%)17 (12%)
18144 (99%)144 (99%)
30143 (99%)143 (99%)
40143 (99%)143 (99%)
50143 (99%)143 (99%)
65138 (95%)138 (95%)
75104 (72%)104 (72%)
8590 (62%)90 (62%)

Across all 613 studies, recruiting or not: 32% stop at 75 or younger and 15% at 65; 9% take children; 3% are for women only and <1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Scleroderma, Systemic studies take

Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 129 mo17–60 · 44 studies——
Phase 237 mo24–83 · 48 studies——
Phase 325 mo21–54 · 17 studies——
Interventional, no phase23 mo10–38 · 101 studies—22 mo8–38 · 95 studies
Observational44 mo17–80 · 61 studies—42 mo15–80 · 59 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 613. Browse all 613 → or search them.